AbbVie's New Generation JAK inhibitor Looks Good But CV Specter Looms
Executive Summary
More Phase III data for AbbVie's selective JAK1 inhibitor upadacitinib appear to back a potential best-in-class claim but eyes remain on safety after a death from pulmonary embolism.
You may also be interested in...
Gilead/Galapagos' Trailing JAK1 Filgotinib Boosted By AS Trial
Gilead and Galapagos have more decent clinical data for filgotinib tucked under their belt as the JAK1 inhibitor shows benefit in another indication, ankylosing spondylitis, with a safety profile that remains reassuring.
Filgotinib Shaping Up To Be Success Story For Gilead and Galapagos
Impressive Phase II data for Gilead and Galapagos’ filgotinib in psoriatic arthritis and progress into Phase III for ulcerative colitis suggest that the investigational JAK inhibitor could potentially become a market leader in the class for these and other inflammatory indications.
AAD Roundup: More Data Emerges In Atopic Dermatitis, But Dupixent Maintains Big Lead
Atopic dermatitis (AD) was a hot topic at the AAD meeting based on last year's Dupixent approval and the growing array of new systemic and topical therapies for the skin condition – and the large market those products may address.